**Background**

Uveitis refers to inflammation of the uveal tract. Uveitis is a frequent cause of ocular complications with subsequent visual impairment [1]. Two studies of patient populations in the west coast of the USA have estimated that the incidence of uveitis ranges from 25.6 to 52 cases per 100,000 person-years and the prevalence ranges from 69 to 115 cases per 100,000 persons [2,3]. Interestingly, the lower estimate of incidence and prevalence above are obtained from a study of Veterans Affairs (VA) patients in the Pacific Northwest, pertinent to the current study’s patient population. As uveitis accounts for up to 10% of blindness in the USA and up to 15% worldwide [4], it is a disproportionate cause of visual disability in light of its frequency. Scleritis is inflammation of the sclera, and similar to uveitis, it is primarily due to autoimmune disease [5-8]. Collectively, uveitis and scleritis may be referred to as ocular inflammatory diseases (OID). Treatment for autoimmune OID consists of suppression of inflammation with corticosteroids or immunomodulatory/steroid-sparing medications. Anti-metabolite medications are the most commonly used after corticosteroids [9] and are effective in up to approximately two-thirds of patients [10-12]. Alkylating agents are more effective, but may carry with them greater risks as well [9,13]. Newer agents such as biologic response modifiers hold great promise for the treatment of OID, but may also have increased risks [9].

The use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (the so-called ‘statins’) has been shown to be beneficial in reducing cardiovascular morbidity and mortality [14]. In addition to reducing serum cholesterol levels, statins are also believed to modify atherosclerosis via anti-inflammatory pathways [15]. Multiple studies have suggested that these modulatory effects of statins may be therapeutic in systemic autoimmune disorders [16]. Various studies have examined the possible impact of statins in ophthalmic conditions, including age-related macular degeneration [17-23], glaucoma [24], and diabetic retinopathy [25-27]. Although the role of statins in ocular disease is not fully understood, given the numerous mechanisms by which statins may modify the inflammatory response, we...
sought to investigate the potential impact of statin use on OID.

**Results**

Ninety-two incident cases of OID were identified. Demographic and medical characteristics of all subjects are detailed in Table 1. By design, the mean age of both cases and control subjects was equivalent. There were similar numbers of each race among the two groups; however, the number for whom race was not known was twice as high among the control group. Those with OID were more likely also to have diabetes and hypertension, whereas the prevalence of lipid metabolism disorders was not statistically different between groups.

Table 2 details the statin use characteristics among OID cases and control subjects as well as the unadjusted and adjusted ORs. Stratified analyses for the effect of comorbidities (ischemic heart disease, cerebrovascular disease, lipid metabolism disorders, hypertension, diseases of the arteries, arterioles, and capillaries, and diabetes) on the association between statin use and OID revealed no evidence of such effect (data not shown). Following adjustment for diabetes, lipid metabolism disorders, hypertension, cardiovascular disease, cerebrovascular disease, and arterial disease, a twofold reduction in the risk of OID development was associated with any history of statin use (OR, 0.50; 95% CI, 0.20 to 1.23), although this did not reach statistical significance (p = 0.13). The reduction in the risk of OID was greater as the duration of statin use increased, as seen in Table 2.

**Discussion**

There are several mechanisms by which statins might exhibit anti-inflammatory effects in the eye [28]. Statins are known to inhibit the activation of Rho guanosine triphosphatase (GTPase), a key molecule in the endothelial ICAM-1-mediated pathway that facilitates lymphocyte migration [29-31]. Statins thus inhibit interactions between leukocytes and endothelial cells, preventing leukocyte transmigration from the vasculature, across the blood-retinal barrier [29,32-34]. Endothelial cell nitric oxide synthase expression is up-regulated in the presence of statins, leading to higher levels of nitric oxide, which has protective effects on endothelial cells [35]. Statins also inhibit the formation of oxygen free radicals by endothelial cells [36,37]. Thus, statins may act to stabilize the blood-ocular and blood-retinal barrier, transgression across which enables inflammatory mediators and immune activator cells to enter the anterior chamber, vitreous cavity, and retinal tissues. In addition, statins reduce a number of key inflammatory cytokines, including IL-6, IL-8, and TNF [38,39]. Finally, statins decrease T cell activation by inhibition of GTPase activity [40-43].

**Table 1 Characteristics of OID cases and control subjects**

|                        | OID cases | Control subjects | p value |
|------------------------|-----------|------------------|---------|
| Number of subjects     | 92        | 920              |         |
| Mean age (years)       | 58.2      | 58.1             | 0.97    |
| Ethnicity              |           |                  | 0.0018  |
| White                  | 48 (52.2) | 378 (41.1)       |         |
| African-American       | 30 (32.6) | 207 (22.5)       |         |
| Other                  | 0 (0)     | 6 (0.6)          |         |
| Unknown                | 14 (15.2) | 329 (35.8)       |         |

| Medical characteristics | | |
|------------------------|--|--|
| Diabetes               | 24 (26.1) | 95 (10.3) | <0.0001 |
| Lipid metabolism disorders | 7 (7.6) | 53 (5.8) | 0.47    |
| Hypertension           | 32 (34.8) | 185 (20.1) |   |
| Cardiovascular disease | 12 (13.0) | 141 (15.3) | 0.56    |
| Cerebrovascular disease| 2 (2.2)   | 47 (5.1)   | 0.21    |
| Arterial disease       | 3 (3.3)   | 32 (3.5)   | 0.91    |

The effect of statins in animal models of uveitis has been examined. In a mouse model using B10.RIII mice, a strain that is highly susceptible to experimental autoimmune uveitis (EAU) and typically manifests severe disease, Thomas and colleagues [44] found that atorvastatin administered orally did not have a significant effect on measured levels of inflammatory cytokines, although they did observe a mildly reduced level of histological inflammation in the group receiving high-dose (10 mg/kg/day) treatment. Similarly, Gegg and colleagues [45] reported that neither atorvastatin nor lovastatin administered orally demonstrated a significant therapeutic effect. However, parenteral lovastatin (20 mg/kg/day) suppressed clinical ocular pathology, retinal vascular leakage, and leukocyte infiltration into the retina. In a rat model of uveitis induced with S-antigen, Kohno and coworkers [46] demonstrated a therapeutic effect for both atorvastatin (10 mg/kg/day) administered orally and lovastatin (2 mg/kg/day) administered intraperitoneally. These studies suggest that the effect of statins varies by route of administration, dosage, as well as across different models of EAU. This data indicates that the potential beneficial effects of statins in EAU may require doses greater than those used in the routine treatment of hyperlipidemia in humans. For example, the highest recommended dose of atorvastatin in humans is 80 mg/day, which for a 70-kg male adult is 1.14 mg/kg/day, ninefold lower than the effective dose used by Kohno and colleagues [46]. In the current study, it is likely that the majority of filled statin prescriptions were for simvastatin, as this was the first line medication on the BVAMC formulary for hyperlipidemia during the study period. The BVAMC data set did not include medication...
dosage information, so we are unable to comment on an association between dosage and OID protection.

The current study has numerous limitations. First, the database consisted exclusively of an older veteran population, and the study was limited entirely to male subjects. This may have introduced a population selection bias in that the incidence of OID in this somewhat homogenous group may be higher or lower than that found among other populations [2,3], including women. However, the homogeneous study population makes these results all the more applicable to the demographic of Caucasian males. Second, the diagnoses of OID were made by individual physicians without the use of standardized criteria, which could introduce differences relative to other studies. However, there is no reason to expect the diagnosis of OID to have been biased by the use of statins. Multiple forms of OID (Table 3) were combined for analysis, with varying etiologies and effects on ocular health. This potpourri of OID introduces additional variability in comparison with other study populations. In addition, if a patient presented as a new VA patient but with longstanding OID, that patient would have been classified as an incident case as opposed to a prevalent case. Because of the nature of the database, adjudication of each OID case to verify whether it was incident or prevalent was not possible. Third, the diagnoses were subject to miscoding into ICD-9CM codes; again, there is no reason to suspect that this would introduce bias. Fourth, statin use was defined on the basis of a filled prescription within the BVAMC pharmacy service. In this scenario, a patient with a statin prescription record but no matching fill record would be classified as a non-statin user, even if he did use statins by filling the prescription outside the BVAMC system. Such miscategorization, however, would only bias toward the null. Additionally, since more than 90% of statin prescriptions were filled at the BVAMC, this is unlikely to have produced a significant effect. We also did not have information on statin use outside the Veterans Affairs system and therefore could have underestimated some subjects’ duration of use. As long as such misclassification is not differential according to case status, then the effect is likely to be minimal. Fifth, race was unknown for a large portion of the control subjects. Additional potentially confounding demographic factors, such as smoking, which has recently been shown to be associated with uveitis [47,48], were also not available.

Strengths of this study include its nested case–control design, which allowed for the identification of statin use before the diagnosis of OID. Additionally, an electronic prescription record was utilized, obviating the need to rely on self-reported medication use which may be historically inaccurate.

Conclusions

In summary, the data presented demonstrate a possible reduction in the risk of the development of OID in patients using statins, a reduction that becomes more pronounced with increasing duration of use. This effect did not reach statistical significance, with a p value of 0.13 for any use of statins. It is important not to overemphasize this finding given the non-significance, but it is important not to reject an effect out of hand in an underpowered study. A twofold reduction in risk, with a p value trending toward significance, may be statistically insignificant, but still clinically relevant. To fully address the question of the effect of statin use on OID risk, evaluation of larger databases with longer follow-up periods, such as insurance company claim files where both disease and pharmacy data are maintained, could provide a definitive answer. A randomized clinical trial would be necessary to establish whether statins would be a useful addition to the therapeutic arsenal against OID.
Methods

Study population and data source

The Birmingham Veterans Affairs Medical Center (BVAMC) is a 134-bed acute tertiary care medical facility and referral center in Alabama. All patients who had at least one visit (inpatient or outpatient) at the BVAMC between 01 January 1997 and 31 December 2001 were eligible for study inclusion. Females were excluded as they represented such a small proportion of the patient population (10.8%) that meaningful analyses were impossible.

The BVAMC provided data files containing demographic information (age, sex, race) and clinical and medication information for each patient. The clinical file contained a description of each diagnosis made at the BVAMC during inpatient and outpatient visits and the diagnosis date. All diagnoses were coded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM). The medication file contained information on each medication prescribed during each patient visit. This file also contained the prescription date and the date the prescription was filled. For both the clinical and medication files, the information provided pertained to all diagnoses and medications over the course of each patient’s history with the BVAMC and not just those that occurred in 1997 to 2001. All data were coded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM). The medication file contained information on each medication prescribed during each patient visit. This file also contained the prescription date and the date the prescription was filled. For both the clinical and medication files, the information provided pertained to all diagnoses and medications over the course of each patient’s history with the BVAMC and not just those that occurred in 1997 to 2001. All data received from the BVAMC contained no information that would allow patients to be identified. The Birmingham Veterans Affairs Medical Center IRB approved the study prior to data collection and analysis. All methods complied with HIPAA guidelines. These data files were locked for the indicated time period, and no additional data on the BVAMC population has been made available since 2001, limiting the study period to that indicated above.

Study design

Within the study population, a nested case–control study was conducted. Cases of OID were defined using the ICD-9CM codes indicated in Table 3. Information on the OID diagnosis date was procured and will heretofore be referred to as the index date. Because this study addressed the association between statin use and the incidence of OID, patients who had an OID diagnosis before the observation period (1997 to 2001) of the study (prevalent cases) were excluded.

Table 3 ICD-9CM codes used

| ICD-9 | Diagnosis                        |
|-------|----------------------------------|
| 136.10| Behçet’s disease                 |
| 360.02| Panophthalmitis                  |
| 360.11| Sympathetic uveitis              |
| 360.12| Panuveitis                       |
| 360.19| Phacoanaphylactic uveitis        |
| 362.18| Retinal vasculitis               |
| 363.00| Focal chorioretinitis, unspecified |
| 363.01| Focal chorioiditis and chorioretinitis, justapapillary |
| 363.03| Focal chorioiditis and chorioretinitis of other posterior pole |
| 363.04| Focal chorioiditis and chorioretinitis, peripheral |
| 363.05| Focal retinitis and retinochoroiditis, justapapillary |
| 363.06| Focal retinitis and retinochoroiditis, macular or paramacular |
| 363.07| Focal retinitis and retinochoroiditis of other posterior pole |
| 363.08| Focal retinitis and retinochoroiditis, peripheral |
| 363.10| Disseminated chorioretinitis, unspecified |
| 363.11| Disseminated chorioiditis and chorioretinitis, posterior pole |
| 363.12| Disseminated chorioiditis and chorioretinitis, peripheral |
| 363.13| Disseminated chorioiditis and chorioretinitis, generalized |
| 363.14| Disseminated retinitis and retinochoroiditis, metastatic |
| 363.15| Disseminated retinitis and retinochoroiditis, pigment epitheliopathy |
| 363.20| Chorioretinitis, unspecified |
| 363.21| Pars planitis                     |
| 363.22| Harada’s disease                  |
| 364.00| Acute and subacute iridocyclitis  |
| 364.01| Primary iridocyclitis             |
| 364.02| Recurrent iridocyclitis           |
| 364.03| Secondary iridocyclitis, infectious |
| 364.04| Secondary iridocyclitis, noninfectious |
| 364.10| Chronic iridocyclitis             |
| 364.11| Chronic iridocyclitis in diseases classified elsewhere |
| 364.20| Certain types of iridocyclitis    |
| 364.21| Fuchs’ heterochromic iridocyclitis |
| 364.22| Glaucomatocycic crises            |
| 364.23| Lens-induced iridocyclitis        |
| 364.24| Vogt-Koyanagi syndrome            |
| 364.30| Unspecified iridocyclitis         |
| 365.62| Glaucoma associated with ocular inflammations |
| 366.32| Cataract in inflammatory disorders |
| 379.00| Scleritis, unspecified            |
| 379.01| Episcleritis periodica fugax      |
| 379.02| Nodular episcleritis              |
| 379.03| Anterior scleritis                |
| 379.04| Scleromalacia perforans           |
| 379.05| Scleritis with corneal involvement |
| 379.06| Branny scleritis                  |
| 379.07| Posterior scleritis               |
| 379.09| Other scleritis                   |

Table 3 ICD-9CM codes used (Continued)
Controls were randomly selected from the study population who did not have an OID diagnosis by the end of the observation period. To be considered an eligible control for a given case, the control must have had an encounter with the BVAMC (inpatient or outpatient) on or before the index date of the matched case. Ten controls were selected for each case and matched on age (±1 year). Each control was assigned the index date associated with their matched case.

The prescription file was queried for the presence of filled statin (atorvastatin, cerivastatin, fluvastatin, pravastatin, simvastatin, lovastatin) prescriptions. Only those prescriptions that were filled before the index date for each matched set of cases and controls were considered. Patients were classified as being either statin users or non-statin users. Statin users were further classified as current or past users, with the former being those who had a statin prescription filled within 6 months before the index date and the latter being those whose last prescription fill date was more than 6 months before the index date.

Information on the presence of the following conditions was extracted from the clinical data file: ischemic heart disease (ICD-9CM codes 410 though 414), cerebrovascular disease (ICD-9CM codes 430 though 438), lipid metabolism disorders (ICD-9CM code 272), hypertension (ICD-9CM codes 401 though 405), diseases of the arteries, arterioles, and capillaries (ICD-9CM codes 440 through 448), and diabetes (ICD-9CM code 250). For the purposes of analysis, only those diagnoses that were recorded before the index date were considered.

Statistical analysis
Conditional logistic regression was used to calculate an odds ratio (OR) and 95% confidence interval (CI) for the association between any statin use and the risk of developing OID. Odds ratios and 95% confidence intervals were also estimated for current and past statin users relative to non-users and according to time since first prescription. Stratified analyses were conducted to determine if ischemic heart disease, cerebrovascular disease, lipid metabolism disorders, hypertension, diseases of the arteries, arterioles, and capillaries, and diabetes modified the association between statin use and OID. For both unstratified and stratified analyses, estimates were obtained without and with adjustment for diabetes, lipid metabolism disorders, hypertension, ischemic heart disease, cerebrovascular disease, and arterial disease.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JJY participated in the conceptualization and design of the study, carried out the ICD code review and selection, and drafted the initial manuscript. GM participated in the conceptualization and design of the study and carried out all statistical analyses. RWR participated in the conceptualization and design of the study and wrote the final draft of the manuscript. All authors read, participated in revising, and approved the final manuscript.

Authors’ information
RWR is a Research to Prevent Blindness physician scientist.

Acknowledgments
This work was supported by unrestricted departmental grants from the EyeSight Foundation of Alabama, Birmingham, AL, and Research to Prevent Blindness, New York, NY. Dr. Read is a Research to Prevent Blindness Physician Scientist.

Author details
1Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, 700 18th Street South, Suite 601, Birmingham, AL 35233, USA. 2Retina Consultants of Alabama, 700 18th Street South, Birmingham AL35233, USA. 3Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 700 18th Street South, Birmingham, AL 35233, USA. 4Department of Surgery, School of Medicine, University of Alabama at Birmingham, 700 18th Street South, Birmingham, AL 35233, USA. 5Department of Pathology, School of Medicine, University of Alabama at Birmingham, 700 18th Street South, Birmingham AL35233, USA.

Received: 18 October 2012 Accepted: 18 October 2012
Published: 11 January 2013

References
1. Wakefield D, Chang JH (2005) Epidemiology of uveitis. Int Ophthalmol Clin 45(2):1–13
2. Suhler E, Lloyd M, Choi D, Rosenbaum J, Austin D (2008) Incidence and prevalence of uveits in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 146(6):890–896
3. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in northern California: the northern California epidemiology of uveitis study. Ophthalmology 111:491–500
4. Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14(5–6):303–308
5. McCannel CA, Holland GN, Helm CJ, Cornell P, Winston J, Rimmer TG (1996) Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 121(1):35–46
6. Henderly DE, Genstler AJ, Smith RE, Rao NA (1987) Changing patterns of uveitis. Am J Ophthalmol 103(2):131–136
7. Merrill PT, Kim J, Cox TA, Betor CC, McCallum RM, Jaffe GJ (1997) Uveitis in the southeastern United States. Curr Eye Res 16:865–874
8. Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D’Amico DJ, Foster CS (1996) Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 114(5):593–599
9. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, Helbarger KU, Jabs DA, Kacmaz RO, Levy-Clarke GA, Liesegang TL, Newcomb CW, Nussenblatt RB, Pujari SS, Rosenbaum JT, Suhler EB, Thorne JE (2009) Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 339:b2480
10. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH (2010) Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 149(3):e421–e422
11. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116(1):218–2198, e2181
12. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148(4):50–509, e502
13. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Foster CS (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117(2):356–365
